These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 14612152)

  • 41. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter.
    Pifl C; Drobny H; Reither H; Hornykiewicz O; Singer EA
    Mol Pharmacol; 1995 Feb; 47(2):368-73. PubMed ID: 7870046
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis and monoamine transporter binding properties of 3beta-(3',4'-disubstituted phenyl)tropane-2beta-carboxylic acid methyl esters.
    Carroll FI; Blough BE; Nie Z; Kuhar MJ; Howell LL; Navarro HA
    J Med Chem; 2005 Apr; 48(8):2767-71. PubMed ID: 15828814
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rapid regulation of the dopamine transporter: role in stimulant addiction?
    Zahniser NR; Sorkin A
    Neuropharmacology; 2004; 47 Suppl 1():80-91. PubMed ID: 15464127
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Localization of the delta-opioid receptor and dopamine transporter in the nucleus accumbens shell: implications for opiate and psychostimulant cross-sensitization.
    Svingos AL; Clarke CL; Pickel VM
    Synapse; 1999 Oct; 34(1):1-10. PubMed ID: 10459166
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Probing dopamine transporter structure and function by Zn2+-site engineering.
    Loland CJ; Norgaard-Nielsen K; Gether U
    Eur J Pharmacol; 2003 Oct; 479(1-3):187-97. PubMed ID: 14612149
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structure-activity relationship comparison of (S)-2beta-substituted 3alpha-(bis[4-fluorophenyl]methoxy)tropanes and (R)-2beta-substituted 3beta-(3,4-dichlorophenyl)tropanes at the dopamine transporter.
    Zou MF; Kopajtic T; Katz JL; Newman AH
    J Med Chem; 2003 Jul; 46(14):2908-16. PubMed ID: 12825932
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protein tyrosine kinase inhibitors alter human dopamine transporter activity in Xenopus oocytes.
    Doolen S; Zahniser NR
    J Pharmacol Exp Ther; 2001 Mar; 296(3):931-8. PubMed ID: 11181926
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vivo interaction of cocaine with the dopamine transporter as measured by voltammetry.
    Greco PG; Garris PA
    Eur J Pharmacol; 2003 Oct; 479(1-3):117-25. PubMed ID: 14612143
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway.
    Jakowec MW; Nixon K; Hogg E; McNeill T; Petzinger GM
    J Neurosci Res; 2004 May; 76(4):539-50. PubMed ID: 15114626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel azido and isothiocyanato analogues of [3-(4-phenylalkylpiperazin-1-yl)propyl]bis(4-fluorophenyl)amines as potential irreversible ligands for the dopamine transporter.
    Cao J; Lever JR; Kopajtic T; Katz JL; Pham AT; Holmes ML; Justice JB; Newman AH
    J Med Chem; 2004 Dec; 47(25):6128-36. PubMed ID: 15566284
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.
    Watanabe Y; Himeda T; Araki T
    Med Sci Monit; 2005 Jan; 11(1):RA17-23. PubMed ID: 15614202
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tyrosine hydroxylase and dopamine transporter expression in residual dopaminergic neurons: potential contributors to spontaneous recovery from experimental Parkinsonism.
    Rothblat DS; Schroeder JA; Schneider JS
    J Neurosci Res; 2001 Aug; 65(3):254-66. PubMed ID: 11494360
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Substrates dissociate dopamine transporter oligomers.
    Chen N; Reith ME
    J Neurochem; 2008 May; 105(3):910-20. PubMed ID: 18088380
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Zinc potentiates an uncoupled anion conductance associated with the dopamine transporter.
    Meinild AK; Sitte HH; Gether U
    J Biol Chem; 2004 Nov; 279(48):49671-9. PubMed ID: 15358780
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of the dopamine transporter gene expression and binding sites in cultured human amniotic epithelial cells.
    Elwan MA; Ishii T; Sakuragawa N
    Neurosci Lett; 2003 May; 342(1-2):61-4. PubMed ID: 12727318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular mechanisms involved in transport and release of dopamine in primary cultures of mesencephalic neurons.
    Hanbauer I; Grilli M
    Neurochem Int; 1992 Mar; 20 Suppl():101S-105S. PubMed ID: 1365405
    [No Abstract]   [Full Text] [Related]  

  • 57. Dopamine action and metabolism in the kidney.
    Aperia A
    Curr Opin Nephrol Hypertens; 1994 Jan; 3(1):39-45. PubMed ID: 7850410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cellular effects of dopamine--beyond oxidative mechanisms.
    Pifl C; Kattinger A; Reither H; Hornykiewicz O
    Parkinsonism Relat Disord; 2002 Sep; 8(6):433-7. PubMed ID: 12217632
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SLC15A4 inhibitor blocks inflammation.
    Crunkhorn S
    Nat Rev Drug Discov; 2024 Mar; 23(3):174. PubMed ID: 38326471
    [No Abstract]   [Full Text] [Related]  

  • 60. What can be learned from studies of multisubstrate mechanisms of neuronal dopamine transport?
    Schenk JO; George SE; Schumacher PD
    Eur J Pharmacol; 2003 Oct; 479(1-3):223-8. PubMed ID: 14612152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.